- Home
- GITS vs CDIO Comparison
GITS vs CDIO Comparison
Compare GITS & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | CDIO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | South Korea | United States |
| Employees | 12 | 17 |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 4.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GITS | CDIO |
|---|---|---|
| Price | $1.44 | $1.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.6K | ★ 61.0K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $171,906.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.97 |
| 52 Week High | $7.09 | $7.91 |
Technical Indicators
Market Signals| Indicator | GITS | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 30.14 |
| Support Level | $1.10 | $1.18 |
| Resistance Level | $2.40 | $2.13 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 55.84 | 13.63 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.